FDA-approved
Immune & defense
Enfuvirtide
Evidence
FDA approved
Class
HIV fusion inhibitor peptide
KEY TAKEAWAY
Enfuvirtide is a 36-amino-acid synthetic peptide that mimics part of the HIV envelope protein gp41. It is sold as Fuzeon. The FDA approved enfuvirtide (Fuzeon) in 2003 as the first HIV fusion inhibitor, for people who had already tried other HIV drugs.
Written by the Veylo editorial team · Updated
November 2026
What it is
HIV fusion inhibitor peptide
Approved for
HIV-1 infection that has resisted other treatments
Key fact
The FDA approved enfuvirtide (Fuzeon) in 2003 as the first HIV fusion inhibitor, for people who had already tried other HIV drugs.
Route
Twice-daily subcutaneous injection
Evidence strength
FDA approved
Enfuvirtide is a 36-amino-acid synthetic peptide that mimics part of the HIV envelope protein gp41. It is sold as Fuzeon.
It binds gp41 and stops the virus from fusing with and entering human immune cells.
The FDA approved enfuvirtide (Fuzeon) in 2003 as the first HIV fusion inhibitor, for people who had already tried other HIV drugs.
HIV-1 infection that has resisted other treatments.
Injection-site reactions are very common. Bacterial pneumonia and allergic reactions are less common but serious.
U.S. FDA prescribing information for Enfuvirtide. DailyMed, National Library of Medicine.
Veylo content is educational and not medical advice. Peptides that are not FDA-approved are not approved for the uses described.